From a cellular medicinal viewpoint, Relafen 750 (naproxen sodium) signifies a compelling case study in noncopyrightal anti-inflammatory agent action. Its process of alleviating inflammation and pain copyrights primarily on the suppression of cyclooxygenase (COX) proteins , specifically COX-1 and COX-2. Analyzing the selective nuances of this inter